913649-99-7

Upstream product

• 143-33-9 sodium cyanide 
• 713115-31-2 4-chloro-2-(chloromethyl)phenyl phenylmethyl ether 
• 713115-29-8 {5-chloro-2-[(phenylmethyl)oxy]phenyl}methanol 
• 635-93-8 5-chlorosalicyclaldehyde 
• 100-39-0 benzyl bromide 
• 38544-16-0 2-(benzyloxy)-5-chlorobenzaldehyde 
• 151-50-8 potassium cyanide 

Downstream Products

• 913650-09-6 methyl 2-(5-chloro-2-[(2-phenylmethyl)oxy]phenyl)ethanimidoate hydrochloride 
• 149428-98-8 (5-chloro-2-((phenylmethyl)oxy)phenyl)acetic acid 

Relevant academic research and scientific papers

Novel methylene-linked heterocyclic EP1 receptor antagonists

We describe the SAR, in terms of heterocyclic replacements, for a series of pyrazole EP1 receptor antagonists. This study led to the identification of several aromatic heterocyclic replacements for the pyrazole in the original compound. Investi

OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS

Compounds of formula (I) or a pharmaceutiically acceptable derivative thereof: wherein X, Z, Y', Y'', R1 ,R2a, R2b, and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine σ ligands as potential antipsychotic drugs

Receptor antagonists may be effective antipsychotic drugs that do not induce motor side effects caused by ingestion of classical drugs such as haloperidol. We obtained evidence that 1-(2-dipropylaminoethyl)-4-methoxy- 6H-dibenzo[b,d]pyran hydrochloride 2a had selective affinity for σ receptor over dopamine D2 receptor. This compound was designed to eliminate two bonds of apomorphine 1 to produce structural flexibility for the nitrogen atom and to bridge two benzene rings with a -CH2O- bond to maintain the planar structure. In light of the evidence, N,Y-dipropyl-2-(4-methoxy-3- benzyloxylphenyl)ethylamine hydrochloride 10b was designed. Since compound 10b had eliminated a biphenyl bond of 6H-dibenzo[b,d]pyran derivative 2a, it might be more released from the rigid structure of apomorphine 1 than compound 2a. The chemical modification of compound 10b led to the discovery that N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxyl)phenyl]ethylamine hydrochloride 10g (NE- 100), the best compound among arylalkoxyphenylalkylamine derivatives 3, had a high and selective affinity for σ receptor and had a potent activity in an animal model when the drug was given orally. We report here the design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine derivatives 3.